14-day Premium Trial Subscription Try For FreeTry Free

Nkarta Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 95.10. In total, the insiders bought 11 498 422 and sold 287 564 NKTX shares in the last 100 trades.

Insider Power

(Last 100 transactions)
95.10
Buy 11 498 422 Shares
Sell 287 564 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 18, 2024 Common Stock Sell Trager James 456
Jun 18, 2024 Common Stock Sell Hastings Paul J 1 770
Jun 18, 2024 Common Stock Sell Shook David 456
Jun 18, 2024 Common Stock Sell Hager Alicia J. 727
Jun 18, 2024 Common Stock Sell Brandenberger Ralph 229
Jun 13, 2024 Stock Option (right to buy) Buy George Simeon 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Behbahani Ali 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Ra Capital Management, L.p. 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Scheiner Zachary 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Patterson Leone D 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Dybbs Michael 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Thedinga Angela 22 500
Jun 13, 2024 Stock Option (right to buy) Buy Vratsanos George 45 000
Jun 13, 2024 Buy Vratsanos George 0
Mar 27, 2024 Common Stock Buy Ra Capital Management, L.p. 3 000 000
Mar 27, 2024 Pre- Funded Warrants (Right to Buy) Buy Ra Capital Management, L.p. 3 000 031
Mar 27, 2024 Common Stock Buy George Simeon 1 548 341
Mar 27, 2024 Common Stock Buy George Simeon 451 659
Mar 04, 2024 Common Stock Sell Hastings Paul J 137 642
Mar 01, 2024 Common Stock Sell Hastings Paul J 12 358
Mar 01, 2024 Common Stock Buy Brandenberger Ralph 2 955
Mar 01, 2024 Common Stock Buy Brandenberger Ralph 3 808
Mar 01, 2024 Common Stock Sell Brandenberger Ralph 8 367
Mar 01, 2024 Stock Option (right to buy) Sell Brandenberger Ralph 2 955
Mar 01, 2024 Stock Option (right to buy) Sell Brandenberger Ralph 3 808
Click to get the best stock tips daily for free!

About Nkarta Inc.

Nkarta. Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials... NKTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT